Bausch + Lomb Corporation
↗Bridgewater, New Jersey, USA
Bausch + Lomb is a global eye health company founded in 1853, headquartered in Bridgewater, New Jersey, with operations in approximately 100 countries. The company is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and ophthalmic surgical products. The company operates through three segments: Vision Care (contact lenses, lens solutions), Pharmaceuticals (prescription and OTC eye care products), and Surgical (intraocular lenses and surgical equipment). With approximately 13,500 employees globally, Bausch + Lomb serves patients, healthcare providers, and retailers worldwide. The company went public on May 6, 2022 (NYSE: BLCO) as a subsidiary of Bausch Health Companies, which retained an 88% stake post-IPO.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:-
Industry:Eye Health / Pharmaceuticals / Medical Devices
Sub-Industry:Ophthalmology / Contact Lens Manufacturing
SIZE & FINANCIALS
Employees:10001+
Revenue:$5B-6B
Founded:1853
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:Bausch Health Companies Inc. (88% stake)
STOCK
Exchange:NYSE
Ticker:BLCO
Market Cap:$225M-250M (estimated at ~$17.03/share as of Feb 2026)
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Ophthalmic Solutions, Intraocular Lenses, Contact Lenses, Surgical Devices, Excimer Laser Systems, Minimally Invasive Glaucoma Surgery (MIGS)
Active Trials:5
Trial Phases:Phase 2: 1 | Phase 3: 3 | Phase 4: 1
FDA Approvals:3
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Bausch Health Companies Inc. (88% ownership)
Subsidiaries:Bausch + Lomb International Sarl, Bausch + Lomb Inc. (US), Multiple regional subsidiaries across 100 countries
Key Partnerships:Novaliq (MIEBO co-development, now acquired/partnered), Novartis (XIIDRA acquisition, Sept 2023 for $1.75B + $750M milestones), Johnson & Johnson (Blink portfolio acquisition, 2023), Collaborations Pharmaceuticals (AI drug development partnership), Cirle, Inc. (medical technology research partnership), National Eye Institute (AREDS study collaboration, PreserVision launch)
COMPETITION
Position:Leader
Competitors:Johnson & Johnson Vision, Alcon Laboratories, CooperVision, EssilorLuxottica, Carl Zeiss Meditec, Hoya Corporation, Menicon Co., Allergan (AbbVie subsidiary)
LEADERSHIP
Key Executives:
Brent Saunders - Chairman & Chief Executive Officer
Sam Eldessouky - Executive Vice President & Chief Financial Officer
Al Waterhouse - Executive Vice President, Chief Supply Chain & Operations Officer
T.J. Crawford - Chief Communications Officer
Manisha Narasimhan, Ph.D. - Chief Corporate Development & Digital Officer
Board Members:Brent Saunders (Chairman & CEO), Thomas W. Ross, Sr. (Lead Independent Director), Nathalie Bernier (Independent Director), Andrew C. von Eschenbach (Independent Director), Sarah B. Kavanagh (Independent Director), John A. Paulson (Independent Director), Russel C. Robertson (Independent Director), Richard U. De Schutter (Independent Director), Eduardo C. Alfonso, MD (Director, effective Jan 1, 2026), Steven H. Collis (Director, effective Jan 1, 2026)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Bausch + Lomb Corporation and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Bausch + Lomb Corporation. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.